CSL/UniQure’s Hemgenix To Enter Uncertain EU Market After Regulatory Nod
Executive Summary
The firms’ one-time hemophilia B gene therapy has been approved in the EU just months after a US nod, but concerns remain about its prospects on a market that has seen several setbacks for other gene therapies.
You may also be interested in...
CSL Nabs First ‘Direct Access’ Funding Agreement In France For Its Gene Therapy
CSL’s hemophilia B gene therapy Hemgenix is the first medicine to be granted reimbursement through France’s experimental “direct access” program, several months after England’s HTA body dubbed the one-time product too expensive for national funding.
England: CSL Undeterred By Draft NICE Rejection Of Its £2.6m Hemophilia B Gene Therapy
CSL Behring said it remains confident that a market access agreement for its hemophilia B gene therapy Hemgenix can be reached after England’s HTA body NICE rejected the product because of uncertainties over its long-term benefit and cost-effectiveness.
Nkarta’s AML Update Disappoints, But New Conditioning Regimen Might Improve Response
An awaited update on early data for a CAR-NK therapeutic shows disappointing efficacy and duration, but a different chemotherapy conditioning regimen for lymphodepletion is showing early promise in acute myeloid leukemia.